anti-Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Anticorps

CYP2D6 encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 Protéines (15) et Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 Kits (12) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
CYP2D6 1565 P10635
CYP2D6    
CYP2D6    
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 Anticorps sur anticorps-enligne.fr

Showing 10 out of 180 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Boeuf (Vache) Lapin Inconjugué WB WB Suggested Anti-CYP2D6 Antibody Titration:  0.2-1 ug/ml  ELISA Titer:  1:1562500  Positive Control:  OVCAR-3 cell lysate CYP2D6 is strongly supported by BioGPS gene expression data to be expressed in Human OVCAR3 cells WB Suggested Anti-CYP2D6  Antibody Titration: 0.2-1 µg/mL ELISA Titer: 1:1562500  Positive Control: OVCAR-3 cell lysate  CYP2D6 is strongly supported by BioGPS gene expression data to be expressed in Human OVCAR3 cells 100 μL 2 to 3 Days
$319.00
Détails
Humain Lapin Inconjugué IHC (p), WB Western blot analysis of Cytochrome P450 2D6 using anti- Cytochrome P450 2D6 antibody .  Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each  Lane was loaded with 50ug of sample under reducing conditions.   Lane 1: rat liver tissue lysates,   Lane 2: mouse liver tissue lysates. After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti- Cytochrome P450 2D6 antigen affinity purified polyclonal antibody (Catalog # ) at 0.5 µg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for Cytochrome P450 2D6 at approximately 56KD. The expected band size for Cytochrome P450 2D6 is at 56KD. IHC analysis of Cytochrome P450 2D6 using anti- Cytochrome P450 2D6 antibody . Cytochrome P450 2D6 was detected in paraffin-embedded section of mouse intestine tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1µg/ml rabbit anti- Cytochrome P450 2D6 Antibody  overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen. 100 μg 4 to 6 Days
$280.00
Détails
Boeuf (Vache) Lapin Inconjugué IHC, WB Rabbit Anti-CYP2D6 Antibody  Paraffin Embedded Tissue: Human Kidney Cellular Data: Epithelial cells of renal tubule Antibody Concentration: 4.0-8.0 ug/ml Magnification: 400X WB Suggested Anti-CYP2D6 Antibody Titration:  2.5ug/ml  Positive Control:  Human Liver 100 μL 2 to 3 Days
$249.00
Détails
Humain Lapin Inconjugué WB Western blot analysis of Cytochrome P450 2D6 expression in MCF7 (A), NIH3T3 (B), H9C2 (C) whole cell lysates. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué IP, WB Western blot analysis of Cytochrome P450 2D6 expression in A431 (A), K562 (B), HuvEc (C) whole cell lysates. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué IP, WB Western blot analysis of Cytochrome P450 2D6 expression in A431 (A), K562 (B), HuvEc (C) whole cell lysates. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué WB Western blot analysis of Cytochrome P450 2D6 expression in MCF7 (A), NIH3T3 (B), H9C2 (C) whole cell lysates. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué ELISA, WB Western blot analysis of extracts from 293/HuvEc/MCF-7 cells, using Cytochrome P450 2D6 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
$302.50
Détails
Humain Lapin Inconjugué ELISA, WB Western blot analysis of extracts from HT-29 cells, using Cytochrome P450 2D6 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
$302.50
Détails
Humain Lapin Inconjugué WB   200 μL 13 to 14 Days
$487.50
Détails

Plus d’anticorps contre Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 partenaires d’interaction

Human Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) interaction partners

  1. The study demonstrated that the simultaneous presence of TMDR1, A CYP2D6*4 and A NAT2*7 alleles robustly increased the risk of developing ulcerative colitis by 3.49-fold. The current study suggests that CYP2D6*4 and MDR1 3435 C/T gene polymorphisms may be risk factors for UC susceptibility.

  2. Genotype-determined and directly measured impaired levels of CYP2D6 activity were associated with elevated risk of therapeutic failure. These findings suggest a natural variability in CYP2D6-dependent metabolism of primaquine as a key determinant of therapeutic efficacy against latent P vivax malaria

  3. Allergic individuals with chemical sensitivity differed from allergic patients without chemical sensitivity with regard to the distribution of genotype and phenotype of CYP2D6 polymorphisms

  4. Genetic Variation of CYP2D6 Gene in the Bosnian Population

  5. The impact of CYP2D6 polymorphisms in the tamoxifen resistance mechanism remains unclear. The CYP2D6 gene seems to contribute to decreasing the efficacy of tamoxifen, while the main mechanism responsible for therapy failure, morbidity, and mortality is the progression of the disease

  6. Critical appraisal of the literature provided evidence for the value of comprehensive CYP2D6 genotyping panels in guiding treatment decisions for non-metastatic ER-positive breast cancer patients. Based on this information, it is recommended that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers.

  7. Plasma exposures of tolterodine and its active moiety were significantly increased in subjects with reduced CYP2D6 activity.

  8. Polymorphisms associated with the metabolization process of morphine and other opioid drugs are very relevant in opioid titration and ethnic subgroup differences which have to be taken into account (particularly, for the recommendation grade A for the CYP2D6 polymorphism)

  9. despite the small sample size, maternal prenatal exposure to pesticides, paternal occupation as a traffic warden/police officer, and CYP2D6*4 polymorphism could play a role in the etiology of childhood acute leukemia.

  10. These findings indicate that Chelidonine acted as a mechanism-based inactivator of CYP2D6 and the observed effects may induce potential drug-drug interactions

  11. Studied herb-drug interactions of mistletoe extracts with endoxifen and their associations with inhibition of CYP3A4/5 and CYP2D6 in vitro.

  12. Investigated CYP2D6 alleles, tandem repeats and copy number variants in a Hong Kong population.

  13. Our results indicate that the altered enzyme activity can be attributed to changes in the hydrogen bonding network within the active site, and local structural differences in flexibility, position and shape of the binding pocket. In particular, the increased (CYP2D6*53) or the decreased (CYP2D6*17) activity seems to be related to a change in dynamics of mainly the BC loop due to a modified hydrogen bonding network around

  14. Studied the association of CYP2D6 polymorphisms and phenotypes with Vivax malaria recurrence in patients from the Western Brazilian Amazon, following chloroquine/primaquine combined therapy.

  15. prevalence of CYP2D6*4 1934AA genotype was higher in total HIV patients compared to healthy controls; similarly, CYP2D6*4 1934AA genotype was much more prevalent in HIV patients without hepatotoxicity compared to healthy controls; there was no significant difference in genotype or allele frequencies of CYP2D6*4 1934G/A polymorphism between the patients with hepatotoxicity and those without or healthy controls

  16. CYP2D6 polymorphisms increase vulnerability to tramadol-induced hepatotoxicity.

  17. Hot flash severity during tamoxifen therapy can not be accounted for by CYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen

  18. found a novel haplotype which involves 100C>T without 4180G>C

  19. There was a significant difference in baseline neuropsychological scores among schizophrenia patients with three genotypes of CYP2D6 rs1135840. Also, rs1135840 showed a significant association with change in scores after risperidone treatment. This reflected a smaller change in GG genotype than C allele carriers; comparison of these two genotype groups gave a significant difference.

  20. The ratio dehydro-aripiprazole/aripiprazole was influenced by CYP2D6 phenotype

Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) profil antigène

Profil protéine

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 20% of commonly prescribed drugs. Its substrates include debrisoquine, an adrenergic-blocking drug\; sparteine and propafenone, both anti-arrythmic drugs\; and amitryptiline, an anti-depressant. The gene is highly polymorphic in the population\; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. The gene is located near two cytochrome P450 pseudogenes on chromosome 22q13.1. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with CYP2D6

  • cytochrome P450 family 2 subfamily D member 6 (CYP2D6) anticorps
  • cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) anticorps
  • cytochrome 2D6 (CYP2D6) anticorps
  • cytochrome P450, family 2, subfamily D, polypeptide 6 (cyp2d6-b) anticorps
  • cytochrome P450 family 2 subfamily D member 6 S homeolog (cyp2d6.S) anticorps
  • cytochrome P450 family 2 subfamily D member 6 (cyp2d6) anticorps
  • cytochrome P450 2D6 (CYP2D6) anticorps
  • cytochrome P450 2D6-like (LOC100988273) anticorps
  • CPD6 anticorps
  • CYP2D anticorps
  • cyp2d2 anticorps
  • CYP2D6 anticorps
  • cyp2d6-a anticorps
  • CYP2D7AP anticorps
  • CYP2D7BP anticorps
  • CYP2D7P2 anticorps
  • CYP2D8P2 anticorps
  • CYP2D42 anticorps
  • CYP2DL1 anticorps
  • CYPIID6 anticorps
  • MGC64445 anticorps
  • P450-DB1 anticorps
  • P450C2D anticorps
  • P450DB1 anticorps

Protein level used designations for CYP2D6

cytochrome P450 2D6 , cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2 , cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2 , cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2 , cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2 , cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6 , cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1 , cytochrome P450-DB1 , debrisoquine 4-hydroxylase , flavoprotein-linked monooxygenase , microsomal monooxygenase , xenobiotic monooxygenase , CYPIID6 , cytochrome P450 CYP2D42 , cytochrome P450, family 2, subfamily D, polypeptide 6 , cytochrome P450 2D6-like

GENE ID SPECIES
1565 Homo sapiens
470228 Pan troglodytes
678691 Macaca mulatta
100500743 Felis catus
379479 Xenopus laevis
446878 Xenopus laevis
548436 Xenopus (Silurana) tropicalis
100568286 Ovis aries
100988273 Pan paniscus
Fournisseurs de qualité sélectionnés pour anti-Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Anticorps
Avez-vous cherché autre chose?